BioSpace

Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%

Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.

By BioSpace

1 min read
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights